Inotiv, Inc. reported first‑quarter fiscal 2026 results that fell short of analyst expectations. Total revenue reached $120.9 million, a modest 0.8 % year‑over‑year increase from $119.9 million in the same period last year, but still $5.6 million below the consensus estimate of $126.53 million. The shortfall was driven by a 5.4 % decline in the Research Models & Services (RMS) segment, which generated $72.9 million versus $77.0 million a year earlier, largely because of lower non‑human primate (NHP) volumes sold. In contrast, the Discovery & Safety Assessment (DSA) segment grew 12 % to $48.0 million, supported by a 27 % jump in net awards and a growing backlog of $145.4 million.
The company’s operating loss widened to $16.3 million, up from $15.5 million in Q1 FY2025. The increase was largely attributable to a $2.4 million rise in RMS operating loss, reflecting higher cost pressures and lower revenue in that segment. DSA operating income improved by $1.2 million, offsetting part of the loss, while unallocated corporate costs fell by $0.3 million. Adjusted earnings per share were –$0.83, missing the consensus estimate of –$0.51 and contributing to the broader earnings miss.
Cash and liquidity remained a concern. The company’s cash and cash equivalents stood at $12.7 million, down from $21.7 million at the end of September 2025, while debt remained unchanged at $405.8 million net of issuance costs. The narrowing cash position, combined with a $28.4 million consolidated net loss versus $27.6 million a year earlier, signals ongoing cash burn and a need for disciplined cost management.
Management emphasized continued focus on client service and margin discipline. CEO Robert Leasure Jr. highlighted the strength of the DSA segment, noting that “DSA revenue increased 12 % and net awards grew 27 % year‑over‑year,” but he also acknowledged the challenges in RMS, stating that the company is “optimizing our RMS footprint and managing NHP supply volatility.” The company did not provide new guidance for FY 2026, indicating uncertainty about near‑term demand and cost dynamics.
Market reaction was negative, driven primarily by the revenue miss and the wider‑than‑expected loss. Investors were disappointed that the company failed to meet consensus estimates for both top‑line and bottom‑line metrics, and the widening operating loss and shrinking cash reserves raised concerns about the company’s ability to sustain operations without additional financing.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.